EU watchdog urges weight-loss drug sale suspension
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The European Union's medicines watchdog has recommended a weight-loss drug be taken off the market over fears it could increase the risk of heart attacks and strokes.
The European Medicines Agency (EMEA) on Thursday recommended sibutramine be taken off the market after a six-year investigation involving nearly 10,000 patients.
An agency committee concluded the risks of the drug outweighed the benefits and "recommended the suspension of marketing authorisations for these medicines across the European Union," the EMEA said in a statement.
Sibutramine is contained in medicines including Reductil, Reduxade and Zelium, which are aimed at helping weight loss in overweight patients with other conditions such as diabetes.
"Doctors should no longer prescribe, and pharmacists should no longer dispense the medicine," said the agency.
It added patients using the drug should make an appointment with their doctor to discuss alternative weight loss treatments.
sr/rl
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments